Data Sheet (Cat.No.T14504)

TargetMol

BAY 38-7271

Chemical Properties



CAS No. : 212188-60-8

Formula: C20H21F3O5S

Molecular Weight: 430.44

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	BAY 38-7271 has strong neuroprotective properties.[1] BAY 38-7271 is selective and highly potent and cannabinoid CB1/CB2 receptor agonist. With Kis of 1.85 nM and 5.96 nM for recombinant human CB1 receptor and CB2 receptor, respectively.
Targets(IC50)	Cannabinoid Receptor
In vitro	BAY 38-7271 demonstrates minimal interactions at the micromolar range with other binding sites, including adenosine A3 receptor (IC50 = 7.5 μM), peripheral GABAA benzodiazepine receptor (IC50 = 971 nM), monoamine transporter (IC50 = 1.7 μM), and melatonin ML1 receptor (IC50 = 3.3 μM) [1].
In vivo	BAY 38-7271 (Ed50 = 0.02 mg/kg; i.v. and 0.5 mg/kg; i.p.) induces a potent and dose-de-pendent reduction in core body temperature[1]. BAY 38-7271 (1-1000 ng/kg/h; i.v. infusion; for 4 hours) shows neuroprotective efficacy in the rat SDH model[1]. BAY 38-7271 has low physical dependence liability and is not essentially different from that of other cannabinoid CB1 receptor agonists[1] and it also has neuroprotective efficacy in models of transient and permanent occlusion of the middle cerebral artery and brain edema models[1].

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.3232 mL	11.616 mL	23.232 mL
5 mM	0.4646 mL	2.3232 mL	4.6464 mL
10 mM	0.2323 mL	1.1616 mL	2.3232 mL
50 mM	0.0465 mL	0.2323 mL	0.4646 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Mauler F, et al. BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury. CNS Drug Rev. 2003 Winter;9(4):343-58.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481